Founded in Emeryville, United States, Milagen is dedicated to enhancing the quality of life for cancer patients through innovative diagnostic products. The company’s core mission is to revolutionize cancer management and early detection, focusing on the five major cancers: breast, colorectal, lung, prostate, and ovarian. Milagen has developed and validated blood-based tests that enable earlier detection and monitoring of cancer recurrence, aiming to provide more effective and timely interventions.
Milagen's significant achievements include extensive research and development efforts, resulting in validated diagnostic tests used on thousands of patients. These tests have the potential to significantly impact cancer treatment outcomes by facilitating earlier detection. The company’s work has attracted attention from notable figures in the medical and investment communities, further solidifying its position as a leader in cancer diagnostics. Through its pioneering efforts, Milagen continues to make substantial contributions to the field of oncology.
